Efficacy of the drug maribavir according to clinical studies-Reference-Cited by-同舟云学术

Efficacy of the drug maribavir according to clinical studies

Published:2024-05-07 Issue:2 Volume:102 Page:101-108
ISSN:2412-1339
Container-title:Clinical Medicine (Russian Journal)
language:
Short-container-title:jour

Author:

Drachuk E. S.¹^ORCID,Gubanova A. A.¹^ORCID,Haidbayev I.²^ORCID,Burmistrova V. N.³^ORCID,Andreyanova K. A.¹^ORCID,Hertek Yu. A.⁴^ORCID,Tuchina V. E.⁴^ORCID,Kuzmina S. V.²^ORCID,Kulikova O. V.²^ORCID,Borodina A. R.³^ORCID,Petrakov A. A.³^ORCID,Om S. M.⁵^ORCID,Babyuk V, V.¹^ORCID

Affiliation:

1. Rostov State Medical University of the Ministry of Healthcare of Russia

2. Mari State University

3. A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

4. Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russia

5. North-Western State Medical University named after I.I. Mechnikоv of the Ministry of Healthcare of Russia

Abstract

Modern medicine has a high demand for new drugs for the prevention and treatment of cytomegalovirus (CMV) infection. This review discusses maribavir — an oral antiviral drug with selective multimodal anti-CMV activity for the treatment of adults and children with post-transplant CMV infection resistant to traditional anti-CMV therapy. Despite numerous clinical trials of maribavir, the results of its effi cacy are ambiguous. Alongside successful studies indicating high effi cacy of the drug under review, there are data from statistically unsuccessful studies. The aim of this review is to examine the mechanism of its action on cytomegalovirus infection, viral sensitivity and cross-resistance mechanisms, as well as to summarize the results of clinical trials of the drug.

Publisher

Medical Informational Agency Publishers

Reference43 articles.

1. Haidar G., Boeckh M., Singh N. Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J. Infect. Dis. 2020;221(1):S23–S31. DOI: 10.1093/infdis/jiz454

2. Teira P., Battiwalla M., Ramanathan M. et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–38. DOI: 10.1182/blood-2015-11-679639

3. Khawaja F., Batista M.V., El Haddad L., Chemaly R.F. Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management. Curr. Opin. Infect. Dis. 2019;32(6):565–574. DOI: 10.1097/QCO.0000000000000607

4. Mehta Steinke S.A., Alfares M., Valsamakis A. et al. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. Transpl. Infect. Dis. 2021;23(3):e13521. DOI: 10.1111/tid.13521

5. Biron K.K., Harvey R.J., Chamberlain S.C. et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 2002;46(8):2365–72. DOI: 10.1128/AAC.46.8.2365-2372.2002